Key Highlights

  • Third-quarter Revenue rose 16% to USD 65.4 million from USD 56.4 million, helped by higher Royalty revenue from Eli Lilly, Rayaldee sales and international growth.
  • The net loss was USD 53.5 million, or USD 0.07 per share, against Net Income of USD 21.6 million, or USD 0.03 per share, a year earlier that included a USD 54.6 million gain from discontinued operations.
  • Labcorp agreed on October 14, 2026 to pay USD 722.0 million in cash for most remaining BioReference diagnostics operations, plus up to USD 150.0 million tied to 4Kscore revenues.
  • Cash, cash equivalents and restricted cash were approximately USD 403.2 million at September 30, 2026, while nine-month operating cash use was USD 99.1 million.

Revenue Growth at OPKO Health (NASDAQ:OPK) Meets a Bigger Strategic Shift

OPKO Health (NASDAQ:OPK) filed its Quarterly Report on November 4, 2026 for the period ended September 30. The company now reports two platforms, Global Products and Innovative Biotech, after reclassifying its BioReference diagnostics Business as discontinued operations. Total revenue rose USD 9.0 million to USD 65.4 million. Product revenue rose 11% to USD 41.8 million, with Rayaldee at USD 8.6 million versus USD 7.5 million, and licensing, collaboration and other revenue rose to USD 23.6 million, including USD 5.8 million of royalties from Eli Lilly. Global Products posted Operating Income of USD 6.0 million versus a loss of USD 1.2 million.

Continuing Loss, Discontinued Swing and a USD 5.0 Million Investment Loss

The loss from continuing operations was USD 35.6 million, or USD 0.05 per share, compared with USD 32.9 million, or USD 0.04. Operating loss narrowed to USD 31.4 million as Research and Development rose to USD 32.2 million. Discontinued operations lost USD 18.0 million after earning USD 54.6 million a year earlier, which explains the swing from profit to a net loss of USD 53.5 million. The quarter also included a USD 5.0 million loss from investments in investees. Over nine months, revenue rose 30% to USD 206.5 million and operating loss narrowed to USD 81.4 million from USD 118.9 million.

Labcorp Terms, Royalty Notes and the Cash Position

Under the Labcorp agreement, closing depends on Hart-Scott-Rodino clearance, with no financing condition, and either side may terminate if it has not closed by April 14, 2027. Labcorp would owe a termination fee of about USD 28.9 million if approvals Fail in specified circumstances. On August 13, 2026 the company also sold another USD 125.0 million of senior secured royalty notes, lifting the Facility to USD 375.0 million and adding Eli Lilly royalty receivables to the collateral. Interest expense rose to USD 13.5 million. The filing notes a transition-services period of about twelve months after closing, and the purchase price is subject to revenue-based adjustments.

Where Things Stand

The sale would remove most of the diagnostics business and leave a pharmaceutical and biotech company. OPKO Health (NASDAQ:OPK) would receive USD 722.0 million at closing, which compares with USD 403.2 million of cash today, though the price can adjust with business revenues and the deal still needs antitrust clearance. The continuing business is improving, with revenue up 16%, but it still loses money and spends heavily on research. Next markers are HSR clearance, the closing before April 14, 2027, royalty revenue from Eli Lilly and the pace of pipeline spending.